LANDOS BIOPHARMA, INC.

LANDOS BIOPHARMA, INC. is a biopharmaceutical company focused on the research, development, and clinical translation of novel therapeutics for gastrointestinal and autoimmune diseases. Their core capabilities center on preclinical and clinical-stage drug development, including target identification, lead optimization, pharmacokinetic and pharmacodynamic profiling, and IND-enabling studies. The company specializes in precision medicine approaches, leveraging mechanistic biology and translational biomarkers to advance small molecule and biologic candidates through early-phase trials. Technical expertise includes in vivo disease modeling, biomarker validation, and regulatory strategy for FDA submissions, with a demonstrated focus on patient-centric trial design and translational science. Their differentiation lies in integrating deep disease biology with agile development pathways to de-risk clinical advancement. Award history does not reflect any federal contract awards, and no agency relationships can be inferred from available data. Consequently, there is no evidence of direct engagement with federal procurement entities or performance under government-funded programs. The company operates within the biopharmaceutical industry, with primary activity aligned to NAICS 325412 (Pharmaceutical Preparation Manufacturing), though no formal NAICS codes are associated with their contract history. Their market positioning is that of a private-stage biotech innovator advancing proprietary candidates toward clinical validation, rather than a government contractor delivering services or products under federal solicitation. LANDOS BIOPHARMA, INC. is structured as a privately held entity (2L) headquartered in Blacksburg, Virginia, with no publicly disclosed government certifications. The company maintains a focused operational footprint centered on R&D and clinical development activities, positioning itself as a specialized biopharmaceutical innovator rather than a federal services provider.